The main goal is to identify new drugs for the treatment of Chagas disease. New drugs are needed because the only two drugs currently available are only effective against the early stages of disease and have significant toxicity to the patient. No drug is available to treat the chronic stage. This assay approach is intended to select drugs that will be effective against the early stages of more ..
Depositor Specified Assays
Show more |
| AID | Name | Type | Comment |
|---|---|---|---|
| 1885 | Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication | screening | 303286 hts compounds at singlepoint in T. Cruzi Inhibition: Beta Gal reporter measuring activity |
| 2010 | Luminescence Cell-Based Dose Response HTS Screen to Identify Cytotoxic Compounds of NIH3T3 cells. | confirmatory | 4065 cherrypick compounds at dose in NIH3T3 toxicity: CTG measuring activity set 1 |
| 2044 | Luminescence Cell-Based/Microorganism Dose Confirmation HTS to Identify Inhibitors of T.Cruzi Replication. | confirmatory | 4065 cherrypick compounds at dose in NIH3T3 toxicity: CTG measuring activity set 1 |
| 2396 | Luminescence Cell-Based/Microorganism Confirmation at Dose of Inhibitors of T.Cruzi Infection | confirmatory | 27 drypowder compounds at dose in T. Cruzi Inhibition: Beta Gal reporter measuring activity set 1 |
| 2632 | Fluorescence Cell-Based/Microorganism Screen to Determine Compound Effect on T. cruzi in NIH3T3 Cells | screening | 42 drypowder compounds at dose in T. Cruzi Inhibition: Beta Gal reporter measuring activity set 2 |
| 2586 | Luminescence Cell-Based Secondary HTS screen to identify cytotoxic compounds of NIH3T3 cells | confirmatory | 27 drypowder compounds at dose in NIH3T3 toxicity: CTG measuring activity set 1 |
| 2630 | Luminescence Cell-Based/Microorganism Confirmation at dose of Inhibitors of T.Cruzi Infection | confirmatory | 42 drypowder compounds at dose in T. Cruzi Inhibition: Beta Gal reporter measuring activity set 2 |
| 493197 | Intracellular Trypanosomes Measured in Cell-Based/Microorganism System Using Plate Reader - 2017-01_Inhibitor_Dose_DryPowder_Activity_Set3 | confirmatory | 46 drypowder compounds at dose in T. Cruzi Inhibition: Beta Gal reporter measuring activity set 3 |
| 493247 | NIH/3T3(mouse embryonic fibroblast cell line) toxicity Measured in Cell-Based System Using Plate Reader - 2017-02_Inhibitor_Dose_DryPowder_Activity_Set2 | confirmatory | 46 drypowder compounds at dose in NIH3T3 toxicity: CTG measuring activity set 2 |
| 2294 | Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Infection | confirmatory |
Description:
Primary Collaborators:
Ana Rodriguez, New York University, Ana.Rodriguez@nyumc.org
Esther Bettiol,Merck/Serano,estherbettiol@hotmail.com
Probes:
ML157, ML158, ML164
Biological Relevance:
The main goal is to identify new drugs for the treatment of Chagas disease. New drugs are needed because the only two drugs currently available are only effective against the early stages of disease and have significant toxicity to the patient. No drug is available to treat the chronic stage. This assay approach is intended to select drugs that will be effective against the early stages of disease when parasites are found mainly extracellularly, but also drugs that will be effective against the chronic stage, where parasites are found inside host cells. Therefore we will select drugs that are either trypanostatic (expected to be effective in the acute phase of disease) or trypanocidal (expected to be effective against the chronic stage).
Keywords: Trypanosoma cruzi, Chagas disease
Ana Rodriguez, New York University, Ana.Rodriguez@nyumc.org
Esther Bettiol,Merck/Serano,estherbettiol@hotmail.com
Probes:
ML157, ML158, ML164
Biological Relevance:
The main goal is to identify new drugs for the treatment of Chagas disease. New drugs are needed because the only two drugs currently available are only effective against the early stages of disease and have significant toxicity to the patient. No drug is available to treat the chronic stage. This assay approach is intended to select drugs that will be effective against the early stages of disease when parasites are found mainly extracellularly, but also drugs that will be effective against the chronic stage, where parasites are found inside host cells. Therefore we will select drugs that are either trypanostatic (expected to be effective in the acute phase of disease) or trypanocidal (expected to be effective against the chronic stage).
Keywords: Trypanosoma cruzi, Chagas disease
Comment
The following compounds [SID] were purchased or synthesized for this project:
87219026 87219027 87219028 87219029 87219030 87219031 87219032 87219033 87219034 87219035 87219036 87219037 87219038 87219039 87219040 87219041 87219042 87219043 87219044 87219045 87219046 87219047 87219048 87219049 87219050 87219051 87219052 87556788 87556789 87556790 87556791 87556792 87556793 87556794 87556795 87556796 87556797 87556798 87556799 87556800 87556801 87556802
87219026 87219027 87219028 87219029 87219030 87219031 87219032 87219033 87219034 87219035 87219036 87219037 87219038 87219039 87219040 87219041 87219042 87219043 87219044 87219045 87219046 87219047 87219048 87219049 87219050 87219051 87219052 87556788 87556789 87556790 87556791 87556792 87556793 87556794 87556795 87556796 87556797 87556798 87556799 87556800 87556801 87556802
Result Definitions
| TID | Name | Description | Histogram | Type | Unit | |
|---|---|---|---|---|---|---|
| Outcome | The BioAssay activity outcome | Outcome | ||||
| Score | The BioAssay activity ranking score |  | Integer | |||
| 1 | ML_NUM | ML number assigned to compound. | String |
Additional Information
Grant Number: MH085673-01
Data Table (Concise)
PageFrom: